Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling

Langerhans cell histiocytosis (LCH) is a rare disease that has a variable clinical presentation and unpredictable behavior. Until recently, therapeutic options were limited. Insights into the role of mitogen-activated protein kinase (MAPK) signaling have allowed the increased use of targeted treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Montella, Liliana, Ottaviano, Margaret, Riccio, Vittorio, Picozzi, Fernanda, Facchini, Gaetano, Insabato, Luigi, Giuliano, Mario, Palmieri, Giovannella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698345/
https://www.ncbi.nlm.nih.gov/pubmed/34944576
http://dx.doi.org/10.3390/biomedicines9121759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698345/
https://www.ncbi.nlm.nih.gov/pubmed/34944576
http://dx.doi.org/10.3390/biomedicines9121759

Ejemplares similares